These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

339 related articles for article (PubMed ID: 19110415)

  • 41. The economic value of primary prophylaxis using pegfilgrastim compared with filgrastim in patients with breast cancer in the UK.
    Liu Z; Doan QV; Malin J; Leonard R
    Appl Health Econ Health Policy; 2009; 7(3):193-205. PubMed ID: 19799473
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Cost-effectiveness of adding granulocyte colony-stimulating factor to primary prophylaxis with antibiotics in small-cell lung cancer.
    Timmer-Bonte JN; Adang EM; Smit HJ; Biesma B; Wilschut FA; Bootsma GP; de Boo TM; Tjan-Heijnen VC
    J Clin Oncol; 2006 Jul; 24(19):2991-7. PubMed ID: 16682725
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Granulocyte colony-stimulating factors for febrile neutropenia prophylaxis following chemotherapy: systematic review and meta-analysis.
    Cooper KL; Madan J; Whyte S; Stevenson MD; Akehurst RL
    BMC Cancer; 2011 Sep; 11():404. PubMed ID: 21943360
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Cost-Effectiveness Analysis of Prophylaxis Treatment Strategies to Reduce the Incidence of Febrile Neutropenia in Patients with Early-Stage Breast Cancer or Non-Hodgkin Lymphoma.
    Fust K; Li X; Maschio M; Villa G; Parthan A; Barron R; Weinstein MC; Somers L; Hoefkens C; Lyman GH
    Pharmacoeconomics; 2017 Apr; 35(4):425-438. PubMed ID: 27928760
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Neutrophil recovery in elderly breast cancer patients receiving adjuvant anthracycline-containing chemotherapy with pegfilgrastim support.
    Brugger W; Bacon P; Lawrinson S; Romieu G
    Crit Rev Oncol Hematol; 2009 Dec; 72(3):265-9. PubMed ID: 19596586
    [TBL] [Abstract][Full Text] [Related]  

  • 46. G-CSF in the prevention of febrile neutropenia in chemotherapy in breast cancer patients.
    Krol J; Paepke S; Jacobs VR; Paepke D; Euler U; Kiechle M; Harbeck N
    Onkologie; 2006 Apr; 29(4):171-8. PubMed ID: 16601374
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Cost effectiveness of primary pegfilgrastim prophylaxis in patients with breast cancer at risk of febrile neutropenia.
    Aarts MJ; Grutters JP; Peters FP; Mandigers CM; Dercksen MW; Stouthard JM; Nortier HJ; van Laarhoven HW; van Warmerdam LJ; van de Wouw AJ; Jacobs EM; Mattijssen V; van der Rijt CC; Smilde TJ; van der Velden AW; Temizkan M; Batman E; Muller EW; van Gastel SM; Joore MA; Borm GF; Tjan-Heijnen VC
    J Clin Oncol; 2013 Dec; 31(34):4283-9. PubMed ID: 24166522
    [TBL] [Abstract][Full Text] [Related]  

  • 48. First and subsequent cycle use of pegfilgrastim prevents febrile neutropenia in patients with breast cancer: a multicenter, double-blind, placebo-controlled phase III study.
    Vogel CL; Wojtukiewicz MZ; Carroll RR; Tjulandin SA; Barajas-Figueroa LJ; Wiens BL; Neumann TA; Schwartzberg LS
    J Clin Oncol; 2005 Feb; 23(6):1178-84. PubMed ID: 15718314
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Use of colony-stimulating factors for chemotherapy-associated neutropenia: review of current guidelines.
    Heuser M; Ganser A; Bokemeyer C; ; ;
    Semin Hematol; 2007 Jul; 44(3):148-56. PubMed ID: 17631179
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The use of chemotherapy regimens carrying a moderate or high risk of febrile neutropenia and the corresponding management of febrile neutropenia: an expert survey in breast cancer and non-Hodgkin's lymphoma.
    Gerlier L; Lamotte M; Awada A; Bosly A; Bries G; Cocquyt V; Focan C; Henry S; Lalami Y; Machiels JP; Mebis J; Straetmans N; Verhoeven D; Somers L
    BMC Cancer; 2010 Nov; 10():642. PubMed ID: 21092320
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Pegfilgrastim prophylaxis in patients at different levels of risk for chemotherapy-associated febrile neutropenia: an observational study.
    Fiegl M; Steger GG; Studnicka M; Eisterer W; Jaeger C; Willenbacher W
    Curr Med Res Opin; 2013 May; 29(5):505-15. PubMed ID: 23444969
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Pegfilgrastim: a recent advance in the prophylaxis of chemotherapy-induced neutropenia.
    Waladkhani AR
    Eur J Cancer Care (Engl); 2004 Sep; 13(4):371-9. PubMed ID: 15305906
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Pegfilgrastim vs filgrastim in primary prophylaxis of febrile neutropenia in patients with breast cancer after chemotherapy: a cost-effectiveness analysis for Germany].
    Sehouli J; Goertz A; Steinle T; Dubois R; Plesnila-Frank C; Lalla A; von Minckwitz G
    Dtsch Med Wochenschr; 2010 Mar; 135(9):385-9. PubMed ID: 20180162
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Chronic comorbid conditions associated with risk of febrile neutropenia in breast cancer patients treated with chemotherapy.
    Chia VM; Page JH; Rodriguez R; Yang SJ; Huynh J; Chao C
    Breast Cancer Res Treat; 2013 Apr; 138(2):621-31. PubMed ID: 23468242
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Colony-stimulating factor use and impact on febrile neutropenia among patients with newly diagnosed breast, colorectal, or non-small cell lung cancer who were receiving chemotherapy.
    McCune JS; Sullivan SD; Blough DK; Clarke L; McDermott C; Malin J; Ramsey S
    Pharmacotherapy; 2012 Jan; 32(1):7-19. PubMed ID: 22392824
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Effectiveness of Leukostim, a Russian preparation of granulocyte colony-stimulating factor, in the treatment of chemotherapy-induced neutropenia in patients with malignant tumors].
    Korman DB; Boronovskaia LE; Maslova IA; Andreeva EV; Seregina GV
    Vopr Onkol; 2008; 54(5):639-42. PubMed ID: 19069482
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Pegfilgrastim dosing on same day as myelosuppressive chemotherapy for ovarian or primary peritoneal cancer.
    Schuman SI; Lambrou N; Robson K; Glück S; Myriounis N; Pearson JM; Lucci JA
    J Support Oncol; 2009; 7(6):225-8. PubMed ID: 20380330
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [OPERa Study].
    Tesařová P
    Klin Onkol; 2013; 26(6):425-33. PubMed ID: 24320592
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A prospective cohort study to evaluate the incidence of febrile neutropenia in patients receiving pegfilgrastim on-body injector versus other options for prophylaxis of febrile neutropenia: breast cancer subgroup analysis.
    Mahtani RL; Belani R; Crawford J; Dale D; DeCosta L; Gawade PL; Huynh C; Lawrence T; Lewis S; MacLaughlin WW; Narang M; Rifkin R
    Support Care Cancer; 2022 Jul; 30(7):6135-6144. PubMed ID: 35426046
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Granulocyte growth factors in the treatment of non-small cell lung cancer (NSCLC).
    Grossi F; Tiseo M
    Crit Rev Oncol Hematol; 2006 Jun; 58(3):221-30. PubMed ID: 16697211
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.